Волчаночный нефрит: современные представления о терапии. (Часть II)
https://doi.org/10.47360/1995-4484-2024-377-384
Аннотация
Во второй части обзора представлены современные данные о стратегии терапии волчаночного нефрита с учетом морфологического класса поражения почек, особенностей течения и активности. Описаны подходы к мониторингу и оценке эффективности лечения, проблемы достижения полного и частичного почечного ответа. Дана характеристика классических и инновационных методов терапии.
При поддержке: Статья подготовлена по фундаментальной научной теме FURS-2022-003 № 122040400024-07.
Об авторах
Е. А. Асеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Асеева Елена Александровна
115522, Москва, Каширское шоссе, 34а
С. К. Соловьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34а
Н. Л. Козловская
ФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»
Россия
Россия
117198, Москва, ул. Миклухо-Маклая
А. А. Баранов
ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России
Россия
Россия
150000, Ярославль, ул. Революционная, 5
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
115522, Москва, Каширское шоссе, 34а
119991, Москва, ул. Трубецкая, 8, стр. 2
Список литературы
1. Ward MM. Hospital experience and mortality in patients with systemic lupus erythematosus: Which patients benefit most from treatment at highly experienced hospitals? J Rheumatol. 2002;29(6):1198-1206.
2. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. doi: 10.1136/annrheumdis-2012-201940
3. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ra mon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934-3940. doi: 10.1002/art.20666
4. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3(1):46-53. doi: 10.2215/CJN.03280807
5. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46(4):995-1002. doi: 10.1002/art.10142
6. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007;22(9):2531-2539. doi: 10.1093/ndt/gfm245
7. Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, et al. Management of lupus nephritis: A systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open. 2020;6(2):e001263. doi: 10.1136/rmdopen-2020-001263
8. Londoño Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A. Brief report: Tubulointerstitial damage in lupus nephritis: A comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol. 2018;70(11):1801-1806. doi: 10.1002/art.40575
9. Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigosa JM, López-Longo FJ, Calvo-Alén J, Olivé A, et al.; RELESSER Group, from the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER). Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus (RELESSER). Medicine (Baltimore). 2016;95(9):e2891. doi: 10.1097/MD.0000000000002891
10. Pokroy-Shapira E, Gelernter I, Molad Y. Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: A single-center inception cohort study. Clin Rheumatol. 2014;33(5):649-657. doi: 10.1007/s10067-014-2527-0
11. Ассоциация нефрологов, Научное общество нефрологов России, Общероссийская общественная организация нефрологов «Российское диализное общество». Клинические рекомендации. Диагностика и лечение волчаночного нефрита. М.;2021. [Association of Nephrologists, Scientific Society of Nephrologists of Russia, All-Russian Public Organization of Nephrologists “Russian Dialysis Society”. Clinical guidelines. Diagnosis and treatment of lupus nephritis. Moscow;2021. (In Russ.)]. URL: http://nonr.su/wp-content/uploads/2021/09/Диагностика-и-лечение-волчаночного-нефрита-проект.pdf (Accessed: DD Month 2020).
12. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924
13. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549-557. doi: 10.7326/0003-4819-125-7-199610010-00003
14. Brugos B, Sebestyen L, Tarr T, Vincze Z. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Pharmazie. 2014;69(6):442-444.
15. Mitjavila F, Pac V, Moga I, Poveda R, Vidaller A, Carrera M, et al. Clinicopathological correlations and prognostic factors in lupus nephritis. Clin Exp Rheumatol. 1997;15(6):625-631.
16. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272
17. Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020;79(8):1077-1083. doi: 10.1136/annrheumdis-2020-216965
18. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al.; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895. doi: 10.1056/NEJMoa1014460
19. Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-262. doi: 10.1093/rheumatology/kev311
20. Moroni G, Gatto M, Raffiotta F, Binda V, Frangou E, Lightstone L, et al. Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmun Rev. 2018;17(1):11-18. doi: 10.1016/j.autrev.2017.11.003
21. Grootscholten C, Berden JHM. Discontinuation of immunosuppression in proliferative lupus nephritis: Is it possible? Nephrol Dial Transplant. 2006;21:1465-1469. doi: 10.1093/ndt/gfl208
22. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139
23. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology. 2020;59:29-38. doi: 10.1093/rheumatology/keaa382
24. Laskari K, Tzioufas AG, Antoniou A, Moutsopoulos HM. Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol. 2011;38:1304-1308. doi: 10.3899/jrheum.101249
25. Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, Fanouriakis A. Management of systemic lupus erythematosus: A systematic literature review informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2024 May 22:ard-2023-225319. doi: 10.1136/ard-2023-225319
26. Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, et al.; WIN-Lupus study group. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022;81(10):1420-1427. doi: 10.1136/annrheumdis-2022-222435
27. Anutrakulchai S, Panaput T, Wongchinsri J, Chaishayanon S, Satirapoj B, Traitanon O, et al. A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: An Asian experience. Lupus Sci Med. 2016;3(1):e000120. doi: 10.1136/lupus-2015-000120
28. Rivera F, Mérida E, Illescas ML, López-Rubio E, Frutos MA, García-Frías P, et al.; Glomerular Spanish Glomerular Study Group (GLOSEN). Mycophenolate in refractory and relapsing lupus nephritis. Am J Nephrol. 2014;40(2):105-112. doi: 10.1159/000365256
29. Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27(6):1007-1011. doi: 10.1177/0961203318758505
30. Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study. Lupus. 2013;22(11):1135-1141. doi: 10.1177/0961203313502864
31. Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis. 2018;21(1):200-207. doi: 10.1111/1756-185X.13152
32. Zhang J, Zhao Z, Hu X. Effect of rituximab on serum levels of anti-c1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015;72:197-201. doi: 10.1007/s12013-014-0437-z
33. Contis A, Vanquaethem H, Truchetet ME, Couzi L, Rigothier C, Richez C, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: A chart review. Clin Rheumatol. 2016;35(2):517-522. doi: 10.1007/s10067-015-3166-9
34. Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al. AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219-231. doi: 10.1016/j.kint.2018.08.025
35. Li Y, Palmisano M, Sun D, Zhou S. Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin Pharmacol. 2020;12:83-96. doi: 10.2147/CPAA.S255789
36. Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al.; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219-231. doi: 10.1016/j.kint.2018.08.025
37. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-1838. doi: 10.1136/annrheumdis-2011-200831
38. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi: 10.1016/S0140-6736(10)61354-2
39. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180
40. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272
41. Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383
42. Асеева ЕА, Соловьев СК, Меснянкина АА, Цанян МЭ, Насонов ЕЛ. Опыт применения белимумаба у больных системной красной волчанкой. Научно-практическая ревматология. 2015;53(3):329-335. doi: 10.14412/1995-4484-2015-329-335
43. Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017;32(6):1013-1021. doi: 10.1007/s00467-017-3583-x
44. Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study. Rheumatology (Oxford). 2014;53(9):1570-1577. doi: 10.1093/rheumatology/ket462
45. Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J. Comparative effectiveness of rituximab and common induction therapies for lupus nephritis: A systematic review and network meta-analysis. Front Immunol. 2022;13:859380. doi: 10.3389/fimmu.2022.859380
46. Торгашина АВ, Соловьев СК, Александрова ЕН, РаденскаЛоповок СГ, Насонов ЕЛ. Применение ритуксимаба у больных волчаночным нефритом. Научно-практическая ревматология. 2010;48(4):14-26. doi: 10.14412/1995-4484-2010-1161
47. Цанян МЭ, Соловьев СК, Торгашина АВ, Александрова ЕН, Раденска-Лоповок СГ, Николаева ЕВ, и др. Эффективность терапии ритуксимабом у больных рефрактерной к стандартной терапии системной красной волчанкой при длительном динамическом наблюдении. Научно-практическая ревматология. 2014;52(2):159-168. doi: 10.14412/1995-4484-2014-159-168
48. Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5):539-548. doi: 10.14412/1995-4484-2018-539-548
49. Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461. doi: 10.14412/1995-4484-2019-452-461
50. Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113-121. doi: 10.1016/j.smim.2011.01.009
51. Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27(10):2929-2939. doi: 10.1681/ASN.2016040415
52. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951-2962. doi: 10.1002/art.22044
53. Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med. 2015;2(1):e000112. doi: 10.1136/lupus-2015-000112
54. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196
55. Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.; CD1013 Study Investigators. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. doi: 10.1002/art.39962
56. Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, et al. Clinicalmorphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. doi: 10.2215/CJN.06720615
57. Bomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clin J Am Soc Nephrol. 2016;11(4):547-548. doi: 10.2215/CJN.01880216
58. Oliva-Damaso N, Payan J, Oliva-Damaso E, Pereda T, Bomback AS. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019;26(5):369-375. doi: 10.1053/j.ackd.2019.08.011
59. Lionaki S, Liapis G, Vallianou K, Appel GB, D’Agati VD. The various forms of nephrotic syndrome in a patient with systemic lupus erythematosus. Case Rep Nephrol. 2020;2020:7869216. doi: 10.1155/2020/7869216
60. Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. doi: 10.5414/cnp57120
61. Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: Coincidence or not? Am J Kidney Dis. 2002;40(6):1179-1184. doi: 10.1053/ajkd.2002.36875
62. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. doi: 10.1681/ASN.2004050350
63. Bomback AS. Nonproliferative forms of lupus nephritis: An overview. Rheum Dis Clin North Am. 2018;44(4):561-569. doi: 10.1016/j.rdc.2018.06.003
64. KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:1-276. doi: 10.1016/j.kint.2021.05.021
65. Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study. Lancet Haematol. 2017;4(4):e157-e164. doi: 10.1016/S2352-3026(17)30026-1
66. von Baeyer H. Plasmapheresis in thrombotic microangiopathy associated syndromes: Review of outcome data derived from clinical trials and open studies. Ther Apher. 2002;6(4):320-328. doi: 10.1046/j.1526-0968.2002.00390.x
67. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556-573. doi: 10.1046/j.1365-2141.2003.04049.x
68. Westwood JP, Thomas M, Alwan F, McDonald V, Benjamin S, Lester WA, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: Outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159-1166. doi: 10.1182/bloodadvances.2017008268
69. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, et al.; French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104-111. doi: 10.1097/CCM.0b013e31822e9d66
70. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451-461. doi: 10.1111/j.1365-2141.2006.06448.x
71. Scully M, McDonald V, Cavenagh J, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746-1753. doi: 10.1182/blood-2011-03-341131
72. Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, et al.; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511-522. doi: 10.1056/NEJMoa1505533
73. Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al.; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi: 10.1056/NEJMoa1806311
74. Sciascia S, Yazdany J, Dall’Era M, Fenoglio R, Radin M, Aggarwal I, et al. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study. Ann Rheum Dis. 2019;78(7):1004-1006. doi: 10.1136/annrheumdis-2018-214559
75. Tektonidou MG. Antiphospholipid syndrome nephropathy: From pathogenesis to treatment. Front Immunol. 2018;9: 1181. doi: 10.3389/fimmu.2018.01181
76. Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009
77. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333
78. Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28:218-227. doi: 10.1097/BOR.0000000000000269
79. Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016;15(1):38-49. doi: 10.1016/j.autrev.2015.08.010
80. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al.; European Forum on Antiphospholipid Antibodies. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568-2576. doi: 10.1002/art.22018
81. Diószegi Á, Tarr T, Nagy-Vincze M, Nánásy-Vass M, Veisz R, Bidiga L, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: The beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-1558. doi: 10.1177/0961203318768890
82. Rymarz A, Niemczyk S. The complex treatment including rituximab in the management of catastrophic antiphospholid syndrome with renal involvement. BMC Nephrol. 2018;19:132. doi: 10.1186/s12882-018-0928-z
83. Guillot M, Rafat C, Buob D, Coppo P, Jamme M, Rondeau E, et al. Eculizumab for catastrophic antiphospholipid syndrome – A case report and literature review. Rheumatology (Oxford). 2018;57(11):2055-2057. doi: 10.1093/rheumatology/key228
84. Ruffatti A, Tarzia V, Fedrigo M, Calligaro A, Favaro M, Macor P, et al. Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmun Rev. 2019;18(5):561-563. doi: 10.1016/j.autrev.2019.03.015
85. Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: A case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-288. doi: 10.1007/s10238-019-00565-8
86. Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32(3):466-474. doi: 10.1093/ndt/gfw453
87. Palma LMP, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep. 2021;6:11-23. doi: 10.1016/j.ekir.2020.10.009
88. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. doi: 10.1056/NEJMoa1208981
89. de Holanda MI, Porto LC, Wagner T, Christiani LF, Palma LMP. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36:2859-2867. doi: 10.1007/s10067-017-3823-2
90. Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249-1255. doi: 10.1007/s00296-017-3686-5
Рецензия
Для цитирования:
Асеева Е.А., Соловьев С.К., Козловская Н.Л., Баранов А.А., Насонов Е.Л. Волчаночный нефрит: современные представления о терапии. (Часть II). Научно-практическая ревматология. 2024;62(4):377-384. https://doi.org/10.47360/1995-4484-2024-377-384
For citation:
Aseeva E.A., Solovyev S.K., Kozlovskaya N.L., Baranov A.A., Nasonov E.L. Lupus nephritis. Part II, modern ideas about therapy. Rheumatology Science and Practice. 2024;62(4):377-384. (In Russ.) https://doi.org/10.47360/1995-4484-2024-377-384
Просмотров:
550
Послать статью по эл. почте 